NeuroDawn Pharmaceutical

Focus: NeuroDawn Pharmaceutical is a small-molecule focused biotech company headquartered in Nanjing, China, with a concentrated pipeline in neurology and stroke treatment. The company operates at a pre-revenue or early-stage clinical phase with limited publicly available scale metrics.

Neurology

Profile data last refreshed 2d ago · AI intelligence enriched 2w ago

Open Jobs

About NeuroDawn Pharmaceutical

AI assessmentNot Hiring

No open roles listed right now. Follow NeuroDawn Pharmaceutical to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Late-stage

3 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Y-3 for injection（40mg）

Pharmacokinetic Differences

Phase 1

Clinical Trials (1)

NCT07055412Y-3 for Injection in Patients With Hepatic Insufficiency and Healthy Subjects

Phase 1

Help build intelligence for NeuroDawn Pharmaceutical

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Access to a focused neurology pipeline with 3 Phase 3 programs (Minocycline, Y-6, Y-3) representing near-term regulatory catalysts in the high-need stroke indication
Early-stage environment with 16 active trials across Phase 1-3, offering hands-on involvement in drug development from preclinical transition through late-stage clinical work
Geographic arbitrage opportunity in Nanjing biotech hub with potential lower cost of living and emerging innovation ecosystem in China

Watch Out For

Zero current job openings and unknown employee headcount suggest either dormancy, restructuring, or a very lean operational model with limited growth trajectory
Absence of published financials, revenue data, and detailed company background raises transparency and sustainability concerns for long-term career stability
Heavy stroke focus (11 of 16 programs target ischemic stroke) creates narrow therapeutic portfolio risk; any clinical setback in this indication could cascade across pipeline

Generated by Claude from NeuroDawn Pharmaceutical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Y-3 for injection

Safety

Phase 1

Clinical Trials (1)

NCT06770491A Phase 1 Study of Y-3 in US Healthy Volunteers.

Phase 1

sequentially single use of repaglinide, warfarin and omeprazole or combined with Y-3

Pharmacokinetic Profiles

Phase 1

Clinical Trials (1)

NCT07068841Pharmacokinetic Effect of Y-3 on Repaglinide，Warfarin and Omeprazole in Healthy Participants

Phase 1

Y-4 tables

Healthy Adult Male and Female Volunteers

Phase 1

Clinical Trials (1)

NCT06935682Safety and Pharmacokinetics of Y-4 Tablets in Healthy Subjects

Phase 1

Y-4 tablet

Healthy Male and Female Subjects

Phase 1

Clinical Trials (1)

NCT06935721Pharmacokinetics of Y-4 Tablets With Pregabalin Capsules and Riluzole Tablets in Chinese Healthy Subject

Phase 1

Y-4 tablet

Healthy Male and Female Subjects

Phase 1

Clinical Trials (1)

NCT07013773To Evaluate the Effect of Food on the Pharmacokinetics of Y-4 Tablets in Healthy Subjects

Phase 1

RK-4 injection

Transcranial Bone Marrow Injection

Phase 1/2

Clinical Trials (1)

NCT07166380RK-4 Intracalvariosseous Injection in Treatment of Acute Large Hemispheric Infarction

Phase 1/2

RK-4 injection

Acute Large Hemispheric Infarction Stroke

Phase 2

Clinical Trials (1)

NCT07203521RK-4 Intracalvariosseous Injection in Treatment of Acute Large Hemispheric Infarction

Phase 2

Low-dose Y-6 sublingual tablets

Acute Ischemic Stroke

Phase 2

Clinical Trials (1)

NCT06138834EFfects of Y-6 SUblingual Tablets foR PaTients With AcUte Ischemic StRokE (FUTURE)

Phase 2

Y-6 sublingual tablets

Acute Ischemic Stroke

Phase 2

Clinical Trials (1)

NCT05836766Cilostazol Dexborneol Versus Placebo for Microcirculation Dysfunction After Reperfusion Therapy in Patients With Acute Ischemic Stroke With Large Vessel Occlusion

Phase 2

Y-4 tables

Postherpetic Neuralgia

Phase 2

Clinical Trials (1)

NCT07275762Y-4 to Treat the Postherpetic Neuralgia

Phase 2

Sarecycline Tablet

Ischemic Stroke, Acute

Phase 2

Clinical Trials (1)

NCT05836753Efficacy and Safety of Sarecycline in Patients With Acute Ischemic Stroke After Reperfusion Therapy